Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Current Assets (2016 - 2025)

Editas Medicine (EDIT) has disclosed Current Assets for 11 consecutive years, with $176.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets fell 34.76% to $176.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $176.9 million, a 34.76% decrease, with the full-year FY2024 number at $289.3 million, down 15.11% from a year prior.
  • Current Assets was $176.9 million for Q3 2025 at Editas Medicine, down from $182.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $632.3 million in Q1 2021 to a low of $176.9 million in Q3 2025.
  • A 5-year average of $382.5 million and a median of $356.8 million in 2022 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: skyrocketed 48.74% in 2021, then plummeted 36.16% in 2025.
  • Editas Medicine's Current Assets stood at $507.3 million in 2021, then fell by 29.68% to $356.8 million in 2022, then decreased by 4.46% to $340.8 million in 2023, then decreased by 15.11% to $289.3 million in 2024, then crashed by 38.86% to $176.9 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Current Assets are $176.9 million (Q3 2025), $182.8 million (Q2 2025), and $224.8 million (Q1 2025).